eXIthera is developing novel, potent, selective small molecule FXIa inhibitors designed to prevent thrombosis with limited risk for bleeding side effects and without the need for a reversal agent. The Company has both parental and oral programs in development. 

EP-7041, eXIthera’s parental drug candidate, recently completed a successful Phase 1 clinical study. In the study, EP-7041 was found to be safe and well tolerated in healthy volunteers following single or multiple ascending doses. In addition, the pharmacokinetic and pharmacodynamic profile indicated desired efficacy with minimal potential for bleeding.

eXIthera expects to select an oral development candidate in the coming months. Together, the parental and oral programs have the potential to address the need for an effective anticoagulant without serious bleeding side effects and offer complementary options for both the hospital and out-patient setting.